[18F]FDG PET/CT Radiomics in Untreated Breast Carcinoma: A Review of the Current State and Future Directions

Background/Objectives: [18F]FDG PET/CT radiomics could improve risk stratification in untreated breast carcinoma. Methods: PubMed Central was accessed for full-text English articles (2015–2025) evaluating radiomic features from pretreatment [18F]FDG PET/CT. The Newcastle-Ottawa Scale (NOS) was used to evaluate the risk of bias. Results: Seven studies (1394 patients with a median cohort of about 150 patients) met the inclusion criteria. Radiomics outperformed conventional metabolic measures at predicting pCR to NAC (with the best AUC 0.83 when combining intra- and peritumoral features); differentiating molecular subtypes (AUC 0.856 luminal vs. non-luminal; 0.818 HER2+ vs. HER2−, and 0.888 triple negative vs. others); and assessing androgen receptor (AR) expression. No additional value was found for ER/PR status. Age influenced SUV and texture metrics, especially in triple-negative lesions. Methodological variation was notable: all studies were retrospective, the majority were single-center, only two provided external validation with different protocols of acquisition and segmentation, and at least four distinct software platforms were used for feature extraction and statistical analysis. Conclusions: [18F]FDG PET/CT radiomics shows good potential for predicting neoadjuvant response and molecular profile in breast cancer. However, small, diverse cohorts and non-standardized methodologies limit the evidence. Prospective multicenter studies with standardized acquisition, segmentation and feature extraction are required before clinical use.